Skip to main content

Table 5 Median dose and relative confidential interval values of EGFR/HER2 pathway inhibitors on BTC cell lines.

From: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

  TFK1 EGI-1 HuH28 TGBC1-TKB
Erlotinib Dm (CI) 2.59 μM 5.72 μM >10 >10
  (0.17-3.46) (1.9-7.5)   
Gefitinib Dm (CI) 1.8 μM 2.48 μM >10 >10
  (1.1-2.9) (1.5-4.03)   
Lapatinib Dm (CI) 5.25 μM 4.02 μM 2.02 μM >10
  (1.01-7.2) (1.01-5.9) (1.2-4.62)  
Sorafenib Dm (CI) 6.2 μM 2.06 μM >10 5.9 μM
  (3.1-12.4) (0.45-9.37)   (3.8-7.9)
Everolimus Dm (CI) 0.20 μM 0.5 μM >10 0.42 μM
  (0.02-1.76) (0.1-1.5)   (0.33-0.54)
  1. The Median doses (Dm) and relative confidential interval (CI) of targeted therapies which affected 50% proliferation on the four cell lines (TFK1, EGI-1, HuH28, and TGBC1-TKB) were calculated after 72 hrs of drug treatment.